Invention Grant
- Patent Title: Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
-
Application No.: US16761677Application Date: 2018-11-05
-
Publication No.: US11414466B2Publication Date: 2022-08-16
- Inventor: Erik Fiedler , Ulrich Haupts , Anja Katzschmann , Eva Bosse-Doenecke , Manja Gloser
- Applicant: Navigo Proteins GmbH
- Applicant Address: DE Halle/Saale
- Assignee: Navigo Proteins GmbH
- Current Assignee: Navigo Proteins GmbH
- Current Assignee Address: DE Halle/Saale
- Agency: Jenkins, Wilson, Taylor & Hunt, P.A.
- Priority: EP17200425 20171107
- International Application: PCT/EP2018/080174 WO 20181105
- International Announcement: WO2019/091918 WO 20190516
- Main IPC: C07K14/47
- IPC: C07K14/47

Abstract:
The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases.
Public/Granted literature
- US20210179678A1 FUSION PROTEINS WITH SPECIFICITY FOR ED-B AND LONG SERUM HALF-LIFE FOR DIAGNOSIS OR TREATMENT OF CANCER Public/Granted day:2021-06-17
Information query